A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery
Disease (CAD) patients , male or female and of age ranging between 20-80 years old.